Pharma BD Deal Intelligence
Sobi to acquire CTI BioPharma in $1.7 billion deal for VONJO pacritinib for myelofibrosis.
Vonjo Q4 2024 sales SEK 416 M (vs SEK 322 M Q4 2023).
PACIFICA confirmatory Phase 3: ACTIVE_NOT_RECRUITING; primary completion 2026-10-05; study completion 2028-10-13; updated 2026-04-30.
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Swedish Orphan Biovitrum (Sobi) acquired CTI BioPharma for $9.10 per share in cash (~$1.7 billion), gaining Vonjo (pacritinib), an FDA-approved JAK2/IRAK1 inhibitor for myelofibrosis with severe thrombocytopenia (platelets <50x10^9/L). The all-cash tender closed 22 Sep 2023. Post-close, Vonjo has outgrown the niche framing: Sobi reported Vonjo sales of SEK 416 M in Q4 2024 (up from SEK 322 M in Q4 2023) and SEK 306 M in Q1 2025. The core thesis risk is unresolved: Vonjo remains under accelerated approval, and the confirmatory PACIFICA Phase 3 trial (NCT03165734) is still active with primary completion expected October 2026 — continued approval is contingent on its outcome.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Swedish Orphan Biovitrum AB / CTI BioPharma Corp. (this deal) | 2023 | $1.7B | 60 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Swedish Orphan Biovitrum AB / AstraZeneca PLC (Synagis US rights) | 2018 | $2.3B | 80 |
| Swedish Orphan Biovitrum AB / Arthrosi Therapeutics, Inc. | 2025 | $1.5B | — |
| Swedish Orphan Biovitrum AB / Apellis Pharmaceuticals, Inc. | 2020 | $1.0B | — |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Servier / Shire plc (Oncology Business) | 2018 | $2.4B | 88 |
← Browse all deals · How we score deals
More: 2023 deals · Swedish Orphan Biovitrum AB deals · Hematology deals